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Background: Nonribosomal peptide synthetases (NRPSs) catalyze the 
assembly of a structurally diverse group of peptides by the multiple-carrier 
thiotemplate mechanism. All NRPSs known to date are exclusively type I 
modular enzymes that consist of domains, such as adenylation (A), peptidyl 
carrier protein (PCP) and condensation (C) domains, for individual enzyme 
activities. Although several A and PCP domains have been demonstrated to 
function independently, aminoacylation in trans has been successful only 
between PCPs and their cognate A domains. 
Results: We have identified within the bleomycin-biosynthesis gene cluster 
from Streptomyces verticillus ATCCl5003 the blml gene that encodes a 
discrete PCP protein. We overexpressed the b/m/ gene in fscherichia co/i, 
purified the Blml protein, and demonstrated that apo-Blml can be efficiently 
modified into holo-Blml either in vivo or in vitro by PCP-specific 
4’-phosphopantetheine transferases (PPTases). Unlike the PCP domains in 
type I NRPSs, Blml lacks its cognate A domain and can be aminoacylated by 
Val-A, an A domain from a completely unrelated type I NRPS. 
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Conclusions: Blml represents the first characterized type II PCP. The Blml 
type II PCP, like the PCP domains of type I NRPSs, can be 4’-phospho- 
pantetheinylated by PCP-specific PPTases but is biochemically distinct in that it 
can be aminoacylated by an A domain from a completely unrelated type I 
NRPS. Our results provide for the first time the genetic and biochemical 
evidence to support the existence of a type II NRPS, which might be useful in 
the combinatorial manipulation of NRPS proteins to generate novel peptides. 
Introduction 
Nonribosomal peptides form a large family of natural 
products that includes many clinically valuable drugs such 
as bleomycin (antitumor), cyclosporin (immunosuppres- 
sant) and vancomycin (antibacterial). In contrast to pep- 
tides of ribosomal origin, which are synthesized from 
gene-encoded peptide precursors and are restricted to the 
21 proteinogenic amino acids (including selenocysteine), 
nonribosomal peptides are synthesized by large, multi- 
functional proteins called nonribosomal peptide syn- 
thetases (NRPSs) [l]. NRPSs catalyze the assembly of 
nonribosomal peptides from an exceedingly diverse group 
of precursors, which includes over 300 different residues 
known to date; the peptide products can be linear, cyclic 
or branched, or can be modified even further through acy- 
lation, glycosylation or heterocyclic ring formation, leading 
to remarkable structural and functional diversity [ZA]. 
Following the classification of fatty acid synthases (FASs) 
[S] and polyketide synthases (PKSs) [6], NRPSs known 
to date are found exclusively to be the large multifunc- 
tional enzymes of the type I architecture with modular 
arrangement [Z-4]. A module is defined as a set of dis- 
tinctive domains that encodes all the enzyme activities 
necessary for one cycle of peptide chain elongation and 
the associated modifications. The peptidyl carrier protein 
(PCP) domain (also called the thiolation domain) is 
central to each module [7]. During the entire elongation 
process, the growing peptide intermediates remain teth- 
ered, in a thioester linkage, to the terminal -SH group of 
the 4’-phosphopantetheine prosthetic group of a PCP. 
The number and order of the modules and the type of 
domains within each module on the NRPS protein there- 
fore determine the structural variations of the resulting 
peptide products by dictating the number, order and 
choice of the incorporated amino acids, and the modifica- 
tions associated with a particular elongation cycle. This 
mode of peptide biosynthesis has been termed the multi- 
ple-carrier thiotemplate mechanism [8]. 
A typical NRPS module consists of an adenylation (A) 
domain [9], a PCP domain [7] and a condensation (C; also 
called elongation) domain [lo], and each of these domains 
is characterized by one or a few highly conserved sequence 
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motifs (also called core sequences) [Z+ll]. The recogni- 
tion of the motifs has greatly facilitated the cloning and 
identification of NRPS genes from genomic DNA using 
the polymerase chain reaction (PCR) with primers 
designed on the basis of the motifs [12] or from available 
genome sequences by directly searching the genebank 
using the motifs as signature sequences [13]. The A domain 
activates a specific amino acid as an aminoacyl adenylate at 
the expense of an ATP [9]. The aminoacyl adenylate is 
then transferred to its cognate PCP domain immediately 
downstream, forming an aminoacyl thioester with the ter- 
minal -SH of the 4’-phosphopantetheine prosthetic group 
[3]. Nucleophilic attack at the carbonyl group of the 
aminoacyl thioester of one module by the amino group of 
the aminoacyl thioester from the downstream neighboring 
module results in amide-bond formation, therefore effect- 
ing the amino to carboxyl terminus stepwise assembly of 
the peptide product [1,8]; this process is catalyzed by the 
C domain [IO]. Additional domains have also been identi- 
fied that are responsible for the modification of the 
peptide product, such as an epimerization domain for the 
conversion of L-amino acids to D-amino acids [3], an N- 
methyltransferase domain for the addition of a methyl 
group to the amide nitrogen [3] and a cyclization domain 
for the formation of heterocyclic rings [14]. A thioesterase 
domain is usually found at the distal carboxyl terminus of 
the NRPS, the function of which has been proposed to be 
the release of the full-length peptide product from the 
NRPS protein to terminate biosynthesis [3,15]. A distinct 
Figure 1 
gene encoding a discrete thioesterase has also been found 
within most of the NRPS gene clusters. The latter 
thioesterase has been speculated to liberate mischarged 
NRPS that is blocked by an unspecific thioesterification at 
the PCP domain [3]. 
Individual NRPS modules [15-191 and domains, such as A 
[9,14,19,20], PCP [7,19,21-261 and C domains [lo], have 
also been heterologously expressed in Eschendia co/i and 
biochemically characterized in w&o. These studies not 
only proved directly the proposed functions for individual 
domains but also demonstrated that these domains can 
function independently and act in warn, at least between 
the A domain and PCP. For example, the catalytic effi- 
ciency for aminoacylation in pans between the A and the 
PCP domains of SrfBl (which activates valine in surfactin 
biosynthesis) was shown to be comparable to that for the 
undissected type I enzyme [7]. A similar result was also 
observed for aminoacylation in Pam between the A domain 
of GrsA and the PCP domain of TycA- both the undis- 
sected GrsA and TycA enzymes activate phenylalanine in 
gramicidin S and tyrocidine biosynthesis, respectively [19]. 
Intriguingly, no in tram aminoacylation was detected 
between the A domain of SrfBl and other PCP domains 
such as that of TycA, SrfB2 (which activates Asp in sur- 
factin biosynthesis) or the aryl carrier protein (ArCP) 
domain of EntB (which activates salicylic acid in enter- 
bactin biosynthesis). These results clearly suggested a spe- 
cific protein-protein recognition between the A and PCP 
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domains; the A domain of a type I NRPS therefore 
appeared to be able to transfer the activated aminoacyl 
adenylate only to its cognate PCP domain [19]. Conse- 
quently, although the choice of an incorporating amino 
acid may be determined primarily by the A domain, the 
domain-specific aminoacylation between the A domain and 
its cognate PCP domains certainly could provide additional 
‘gating’ against misincorporation of nonspecifically acti- 
vated aminoacyl adenylate into the final peptide product. 
The bleomycins (BLMs) are a family of glycopeptide- 
derived antitumor antibiotics, and the clinically used drug 
Blenoxanea contains BLM A2 and BLM BZ as the princi- 
pal constituents, which have the same peptide/polyke- 
tide/peptide backbone and differ only at their carboxy- 
terminal amines. We have been studying the biosynthesis 
of BLM as a model system for a hybrid NRPS and PKS 
[27], and have cloned and sequenced a 80 kilobase (kb) 
gene cluster, including the two previously characterized 
bhAB resistance genes [Z&29], for BLM biosynthesis 
from Streptomyces vetii&us (SU) ATCC 15003 (L.D., 
C. Sanchez, M. Chen, D.J. Edwards, B.S., unpublished 
observations). Among the 36 open reading frames (orfs) 
identified within the b/m gene cluster is a PKS gene 
flanked by multiple NRPS genes encoding a total of 
12 putative NRPS modules, a genetic organization in 
agreement with the hybrid NRPS/PKS/NRPS hypothesis 
for BLM biosynthesis. Intriguingly, in addition to the type 
I NRPS and PKS genes, we also identified three orfs, 
blml, !&n/l and b/mXI, the deduced amino acid sequences 
of which are highly homologous to the PCP (BlmI) and C 
(BlmII and BlmXI) domains of type I NRPS, respectively 
(Figure lb). As all NRPS domains known to date exist as 
an integrated part of a type I multifunctional NRPS 
module, the identification of these discrete PCP and C 
proteins suggests a novel type II organization of NRPS, 
reminiscent of type II FASs [5] and PKSs [6]. Here we 
report the heterologous expression of blml in E. co& in 
aivo 4’-phosphopantetheinylation of the BlmI protein by 
the Gsp phosphopantetheinyl transferase (PPTase) [26], 
and in vitro 4’-phosphopantetheinylation of the BlmI 
Figure 2 
protein by the Sfp PPTase [l&23,24], validating BlmI as 
the first characterized type II PCP. Remarkably, in con- 
trast to the type I PCP domains that accept only the 
aminoacyl adenylate from their cognate A domains [7,19], 
the BlmI type II PCP, which has no cognate A domain of 
its own, can be aminoacylated in vitro by an A domain 
from a completely unrelated type I NRPS module. The 
latter property of the BlmI protein implicates a distinct 
strategy for a type II NRPS to assemble peptides and can 
now be exploited directly in the combinatorial manipula- 
tion of NRPS proteins to generate novel peptides. 
Results 
Cloning and sequence analysis of the blml gene 
In our effort to clone the gene cluster responsible for 
BLM biosynthesis, we have determined an 80 kb DNA 
sequence from Sv ATCC15003 (Figure la) [27]. Among 
the 36 orfs identified within the blm gene cluster is a small 
orf of 273 base pairs (bp), bimZ, which is located approxi- 
mately 4 kb upstream of the previously characterized 
blmAB resistance locus [28,29] (Figure 1 b). The bl’mZ gene 
encodes a protein of 90 amino acids that has a molecular 
weight of 9957 and a p1 of 6.52 (Figure lc). Computer- 
assisted analysis [30] of the deduced amino acid sequence 
indicates that BlmI is very similar to various PCP domains 
of NRPSs (around 40% identity and 60% similarity, as 
shown in Figure 2). Like known PCP domains of NRPSs, 
BlmI has the highly conserved signature motif of LGGXS 
(using single-letter amino-acid code, where X is any amino 
acid). The serine residue in this motif is the site for 
4’-phosphopantetheinylation [3,11], which is the post- 
translational modification essential for peptide biosynthe- 
sis because it converts the apo-PCP into the functional 
holo-PCP [3,31]. On the basis of sequence comparison, 
BlmI is most related to PCPs and not to other types of 
carrier proteins that also share the same LGGXS motif and 
undergo the same post-translational 4’-phosphopante- 
theinylation [31], such as the E. coli acyl carrier protein 
(ACP) [32], the ACP domain of type I PKS and the type II 
PKS ACP [33,34], the ArCP domain 1171, and several 
nodulation-related ACP-like proteins [35,36]. 
Amino acid sequence comparison of Blml 
with PCP domains of known type I NRPSs 
(Grs-2 [P14686], 36% identity, 58% 
similarity; Ma-3 [GO8787], 40% identity, 
64% similarity; Vir-S [CAA723101, 36% 
identity, 60% similarity; Saf-6 IAAC441281, 
40% identity, 54% similarity). Protein 
sequence accession numbers are in square 
parentheses. The blue-shaded letters indicate 
similar amino acids. Consensus residues are 
amino acids that are similar in more than three 
sequences. The signature motif for 
Gr6-2 3090 EETE#!EQYRl%-3134 / 
Srfa-3 1005~ DGLQD-1048 
vir-s 602- VRPAL- 646 
Saf-B 1706. TKTHQAR-1750 
BhI 46.,, GERDR- 90 
consensus 46-KA MRV SRV L EV VRVLFE PTVAGLA I G T  - 90 
4’-phosphopantetheinylation is underlined. Chemistry & Biology 
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Overexpression of b/ml in E. co/i Figure 4 
To overexpress the blml gene in E. co& we directly ampli- 
fied the b1mI gene, using PCR, from the Sv. ATCC15003 
genomic DNA and cloned it into the pQE-60 expression 
vector to give pBS1 so that BlmI could be produced as a 
protein with a native amino terminus and a His,-tag at its 
carboxyl terminus. No production of the BlmI protein was 
detected, however, as judged using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
upon introduction of pBS1 into E. coli M15(pREP4) under 
the standard overexpression conditions recommended by 
the manufacturer (Qiagen). We reasoned that the small 
BlmI protein with its native amino terminus may not be 
stable in the heterologous host, and therefore moved the 
b/ml gene from pBS1 into PET-29a to yield the second 
overexpression construct of pBS2. In pBSZ, BlmI should 
be produced as a fusion protein with 27 extra amino acid 
residues at its amino terminus, including an S-tag and the 
thrombin-cleaving site, in addition to the His,-tag at its 
carboxyl terminus. Introduction of pBSZ into E. co/i 
BLZl(DE-3) under the standard overexpression conditions 
recommended by the manufacturer (Novagen) indeed 
resulted in overproduction of BlmI. In fact, the bulk of the 
soluble protein was the overproduced BlmI (Figure 3, 
lane Z), which was easily purified by affinity chromatogra- 
phy using Ni-NTA resin (Qiagen). Fusion of the additional 
27 amino acids to the amino terminus of BlmI as in pBS2 
and change of the expression system from E. co/i 
M15(pREP4) (pBS1) to E. co/i BLZl(DE-3)(pBSZ) there- 
fore dramatically improved the expression level of b/ml. 
W 
HPLC analysis of Blml purified from (a) E. co/i OG7001 (pBS2) and 
(b) E. co/i OG7001 (pBS2/pDPT-Gsp). 
In vivo 4’.phosphopantetheinylation of the Blml protein 
To establish BlmI as a type II PCP, we tested whether it 
could serve as a substrate for a PCP-specific 4’-PPTase. 
PPTases catalyze the post-translational modification of an 
Figure 3 
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Overexpression of b/ml in E. co/i and purification of Blml protein. 
Lane 1, molecular weight markers; lanes 2 and 3, total soluble proteins 
and purified Blml from BL21 (DE3)(pBS2); lanes 4 and 5, total soluble 
proteins and purified Blml from OG7001 (pBS2); lanes 6 and 7, total 
soluble proteins and purified Blml from OG7001 (pBSP/pDPT-Gsp). 
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apo-PCP into a holo-PCP by transferring the 4’-phospho- 
pantetheine moiety from co-enzyme A (CoA) to the con- 
served serine residue of PCP, and this reaction has been 
developed recently into a general method to prepare various 
holo-PCP, holo-ACP or holo-ArCP from the corresponding 
apoproteins [7,17-19,23-25,31,35]. We therefore decided to 
investigate the 4’-phosphopantetheinylation of BlmI under 
both in viva [26] and in v&o [l&23,24] conditions. 
To examine 4’-phosphopantetheinylation of BlmI in &JO, 
we chose E. co& OG7001 as the expression host, which is a 
p-alanine auxotroph derived from E. coli BLZl(DE3) by 
Pl co-transduction of thepanD mutation from E. co/i SJ16 
[35]. Upon introduction of pBS2 into E. coli OG7001, b/ml 
was exceptionally well expressed (Figure 3, lane 4) and the 
overproduced BlmI protein was readily purified (Figure 3, 
lane 5). High-performance liquid chromatography (HPLC) 
analysis showed, however, that the purified BlmI was 
essentially in the apo-form (Figure 4a), indicating that apo- 
BlmI was a poor substrate for the E. coli endogenous 
PPTases, such as EntD and ACP synthase [23,31,32]. To 
circumvent the poor endogenous PPTase activity, we next 
co-expressed b/ml with the gsp gene, which was isolated 
from the gramicidin S producer Bad/us brmis, and 
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encoded a PPTase that was known to 4’-phosphopanteth- 
einylate heterologously produced PCPs in E. cob [23,26]. 
We co-transformed pDPT-Gsp, in which the expression of 
the gsp gene was under the control of the T5/Lac promoter 
[26], and pBS2 into E. coc’i OG7001. As shown in Figure 3 
(lane 6), &nZ was again very well expressed and the result- 
ing BlmI protein was similarly purified (Figure 3, lane 7). 
HPLC analysis showed that at least 60% of overproduced 
BlmI was modified into the holo-BlmI protein (Figure 4b). 
(A PCP domain was similarly 4’-phosphopantetheinylated 
in viva before by co-expressing gsp in E. coli using pDPT- 
Gsp, and approximately 80% of the PCP was produced in 
the holo-form [26].) 
We next cultured E. coli OG7001(pBSZ) and E. coli 
OG7001(pBSZ/pDPT-Gsp) in the presence of [3-3H]- 
p-alanine, a known biosynthetic precursor of 4’-phospho- 
pantetheine [7,3.5]. Specific incorporation of [3-3H]- 
p-alanine into the 4’-phosphopantetheine moiety of 
holo-BlmI was determined by autoradiographic analysis. 
Although fermentation of E. co/i OG7001(pBSZ) in the 
presence of [3-3H]-p- a anine led to an IPTG-dependent 1 
overproduction of BlmI, little of the resulting BlmI protein 
was 3H-labeled, indicating it was produced in the apo-form 
(Figure .Sa,b; lane 2,3). In contrast, fermentation of E. coLi 
OG7001(pBSZ/pDPT-Gsp) in the presence of [3-3H]-p- 
alanine resulted in a significant increase in IPTG-depen- 
dent incorporation of the 3H-label into the overproduced 
BlmI protein (Figure Sa,b; lane 45, suggesting a specific 
incorporation of [3-3H]-P-alanine into holo-BlmI, presum- 
ably in the 4’-phosphopanthetheine moiety. Several addi- 
tional proteins were also weakly labeled by [3-3H]- 
/3-alanine. Both their expression and their incorporation of 
3H-label were independent from either IPTG induction or 
the presence of Gsp, however, hence these proteins were 
unrelated to BlmI. (Similar background labeling was 
reported before for in viva 4’-phosphopantetheinylation of 
other PCPs [35].) We also purified the BlmI protein from 
E. co/i OG7001(pBSZ/pDPT-Gsp) and demonstrated that 
the holo-BlmI protein was specifically associated with the 
3H-activity (Figure Sa,b; lane 6). Finally, we confirmed the 
identity of holo-BlmI by subjecting the purified BlmI 
protein to matrix-assisted laser desorption ionization-time 
of flight (MALDI-TOF) mass spectral analysis [19]. BlmI 
produced in the absence of the Gsp PPTase yielded a 
single peak with a molecular weight of 13,952 Da, suggest- 
ing that the produced BlmI protein is in the apo-form 
(calc’d, 13,949). In contrast, BlmI produced in the pres- 
ence of Gsp yielded two species with molecular weights of 
13,969 and 14,303 Da, respectively. The species with the 
molecular weight of 13,969 Da represents apo-BlmI, 
whereas a molecular weight of 14,303 Da unambiguously 
confirmed the other protein as holo-BlmI (calc’d, 14,289). 
This result indicated that the purified BlmI consisted of 
both the apo- and holo-BlmI proteins, in agreement with 
the HPLC analysis results (Figure 4b). 
Figure 5 
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ln viva incorporation of [3-3H]-5-alanine and in vitro incorporation of 
[sH-pantetheinel-CoA into holo-Blml. (a) Coomassie-Blue-stained 15% 
SDS-PAGE gel and (b) its autoradiogram for in viva labeling of Blml by 
3H-f3-alanine in E. co/i OG7001. Lane 1, molecular weight markers; lanes 
2 and 3, total proteins from OG7001 (pBS2) without and with IPTG 
induction; lanes 4 and 5, total proteins from OG7OOl (pBSP/pDPT-Gsp) 
without and with IPTG induction; lane 6, Blml purified from lane 5. 
(c) Autoradiogram for in vitro labeling of Blml by [3H-pantetheinel-CoA. 
Lane 1, apo-Blml; lane 2, Sfp; lane 3, apo-Blml with Sfp. 
In vitro 4’.phosphopantetheinylation of the Blml protein 
To investigate 4’-phosphopantetheinylation of BlmI in 
vitro, we chose the Sfp protein as the preferred PPTase, 
which had been isolated before from the surfactin pro- 
ducer BaciLhs subtilis [37]. (Overexpression ofgsp in E. cob 
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using pDPT-Gsp resulted predominantly in an insoluble 
Gsp protein [26].) The Sfp PPTase was overproduced in 
E. coli MVll9O(pUCS-Sfp) and purified to near homo- 
geneity as described previously [24,37]. Upon incubation 
of the purified apo-BlmI with [3H-pantetheine]-CoA in 
the presence of the Sfp PPTase, we examined the cova- 
lent incorporation of the [3H-pantetheine]-4’-phospho- 
pantetheine moiety from CoA into holo-BlmI using 
autoradiographic analysis. Indeed, the apo-BlmI was quan- 
titatively labeled by [3H-pantetheinel-CoA (Figure SC; 
lane 3), and no labeling was observed in the absence of 
either the apo-BlmI or the Sfp PPTase protein (Figure SC; 
lane l,Z), demonstrating that the Sfp PPTase can recog- 
nize apo-BlmI as a substrate and specifically transfer the 
4’-phosphopantetheine group from CoA into holo-Blml. 
In vitro aminoacylation of Blml 
Once we established BlmI as a type II PCP that can be 
readily modified by PCP-specific PPTases into the holo- 
BlmI protein, we tested whether the holo-BlmI could be 
aminoacylated in trans, which requires an A domain. As 
BlmI has no cognate A domain of its own, we turned our 
attention to another putative biosynthesis gene cluster we 
cloned previously from Sv ATCC15003, which encodes at 
least three NRPS modules and one PKS module. We have 
established that this gene cluster is not clustered with the 
blm locus and is unrelated to BLM biosynthesis (L.D., 
C. Sanchez, M. Chen, S-M. Lee and B.S., unpublished 
observations). From this gene cluster, we amplified using 
PCR a 1579 bp fragment encoding an A domain, named 
Val-A, which we predicted to have a molecular weight of 
56,581 Da and a p1 of 7.39. We cloned va1-A into PET-28a 
to yield pBS3, in which Val-A would be produced as a 
fusion protein with a His,-tag at the amino terminus. 
Introduction of pBS3 into E. co/i BLZl(DE3) under the 
standard overexpression conditions recommended by the 
manufacturer (Novagen) resulted in good overproduction 
of Val-A, predominantly in soluble form, which was puri- 
fied by affinity chromatography using Ni-NTA resin 
Figure 6 
(Figure 6a). The purified Val-A protein was active as mea- 
sured using the amino-acid-dependent ATP-PPi exchange 
assay [38]. Among the 23 amino acids tested, Val-A specifi- 
cally activated valine, an amino acid that is not required for 
BLM biosynthesis (Figure 6b). 
To carry out the aminoacylation in tram, we incubated the 
purified holo-BlmI and Val-A in vitro in the presence of L- 
[14C(U)]valine and ATP [7,19]. The aminoacylated holo- 
BlmI-L-[14C(U)]valine species was subjected to SDS- 
PAGE and specific attachment of L-[14C(U)]valine to 
holo-BlmI was determined using autoradiographic analy- 
sis. Remarkably, the holo-BlmI was specifically labeled by 
L-[14C(U)]valine in the presence of Val-A, indicative of the 
formation of the holo-BlmI-S-valine thioester (Figure 7; 
lane 5). The in tram aminoacylation between the holo- 
BlmI and Val-A proteins appeared to be very specific. 
Neither incubation of I,-[14C(U)]valine with Val-A 
(Figure 7; lane 1) , the apo-BlmI (Figure 7; lane 2) or the 
holo-BlmI protein (Figure 7; lane 3) alone, nor incubation 
of L-[14C(U)]valine with the Val-A and apo-Blml proteins 
(Figure 7; lane 4), resulted in the detection of 14C-labeled 
BlmI protein. 
Discussion 
Nonribosomal peptides and polyketides are two distinct 
classes of natural products yet they are assembled from 
amino acids and short carboxylic acids by NRPSs and 
PKSs, respectively, using strikingly similar strategies [ 11. 
These fascinating multifunctional enzyme complexes have 
been classified into two types on the basis of their gene 
organization and enzyme architecture. Type I enzymes are 
multifunctional proteins that consist of domains for indi- 
vidual enzyme activities and type II enzymes are multien- 
zyme complexes that consist of discrete proteins that are 
largely monofunctional. Although both type I and type II 
PKSs (Figure 8a,c) have been well characterized to account 
for the vast structural diversities found in polyketide 
biosynthesis [6], all NRPSs studied so far are exclusively 
1 (a) Overexpression of val-A in E. co/i and 
purification of Val-A. Lane 1, molecular 
markers; lanes 2 and 3, total soluble proteins 
and purified Val-1 from BL21 (DE3)(pBS3), 
respectively. (b) Amino acid specificity of 
Val-A as determined using the amino-acid- 
dependent ATP-PPi assay (standard three- 
letter amino-acid designations are used and 
HO-Pro refers to 4-hydroxyproline). 
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the type I modular enzymes (Figure Sb) [Za]. It is very 
tempting to speculate that a type II NRPS exists that, anal- 
ogous to type II PKS [39-41], consists of discrete proteins 
possessing enzyme activities such as the A [9], the PCP [7] 
or the C [lo] domains of type I NRPSs (Figure 8d). The 
fact that both the A [9,14,19,20] and the PCP [7,19,21-261 
domains of type I NRPSs can act as independent enzymes 
supports the hypothesis of a type II NRPS. 
We have now cloned and sequenced the blm1 gene, over- 
produced and characterized the BlmI protein as a bona 
fide type II PCP, and demonstrated that holo-BlmI can 
be aminoacylated by a completely unrelated A domain, 
providing for the first time genetic and biochemical evi- 
dence for a type II NRPS enzyme. We concluded BlmI 
to be a type II PCP on the basis of the following criteria. 
First, the deduced amino acid sequence of the blmml gene 
is highly homologous to various PCP domains of known 
NRPSs, particularly at the signature motif of LGGXS 
within which the 4’-phosphopantetheine prosthetic 
group is covalently attached to the serine residue [3,11]. 
Although the current boundaries for a PCP domain in the 
literature were defined arbitrarily [7] and varied from one 
PCP to another [7,19,21-261, we can now re-define a 
PCP domain for the type I NRPS as a 90 amino acid 
peptide in which approximately 45 amino acids flank 
either side of the the essential serine residue in the 
LGGXS motif, in light of this discrete BlmI type II PCP 
(Figure 2). Second, the b/ml gene has been successfully 
expressed in E. co/i, and fusion of a short peptide to the 
amino terminus of BlmI dramatically improved its over- 
production efficiency. Although we cannot exclude the 
effect of different systems on gene expression (i.e. E. co/i 
MlS(pREP4)(pBSl) compared with E. coli BLZl(DE- 
3)(pBSZ)) we attribute the increase in expression effi- 
ciency to the stability of BlmI as an amino-terminal 
fusion protein instead of the otherwise labile BlmI 
protein with its native amino terminus. As BlmI was pro- 
duced predominantly in the apo-form in E. coli, apo- 
BlmI was apparently not a substrate for the endogenous 
PPTases, such as EntD or ACP synthase, excluding BlmI 
as an ArCP or ACP, respectively. EntD and ACP syn- 
thase are known to 4’-phosphopantetheinylate apo-ArCP 
and apo-ACP, respectively, to their holo-forms efficiently 
[23,31,32]. Third, the apo-BlmI protein serves as a sub- 
strate for PCP-specific PPTases that transfer the 4’-phos- 
phopantetheine moiety from CoA to apo-BlmI to yield 
the holo-BlmI protein. We have demonstrated this post- 
translational modification for BlmI in viva with the Gsp 
PPTase [26] and in vitro with the Sfp PPTase [18,23,24], 
both of which have been extensively used in preparing 
holo-PCPs. Fourth, the specific modification of apo-BlmI 
by 4’-phosphopantetheinylation has been monitored 
using HPLC analysis (Figure 4) [19] and by specific 
incorporation of [3-3H]-B-alanine in viva [7,26,35] and of 
[3H-pantetheinel-CoA in vitro [18,23,24] into the 
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In vitro aminoacylation of holo-Blml by Val-A. (a) Coomassie-Blue- 
stained 15% SDS-PAGE gel and (b) its autoradiogram. Lane 1, Val-A; 
lane 2, apo-Blml; lane 3, holo-Blml; lane 4, apo-Blml with Val-A; lane 5, 
holo-Blml with Val-A; lane 6, molecular weight markers. 
4’-phosphopantetheine moiety of the holo-BlmI protein 
(Figure 5). The identity of BlmI was finally confirmed 
using MALDI-TOF mass spectral analysis [19] that 
determined the molecular weight for both the apo- and 
holo-BlmI proteins. 
Although individual domains of type I NRPSs can func- 
tion independently and several A [9,14,19,20] and PCP 
[7,19,‘21-261 domains have been overproduced, purified 
and biochemically characterized, aminoacylation in tram 
has been successful only between PCPs and their cognate 
A domains [7,19]. No aminoacylation between PCP and 
A domains from different NRPS modules has been 
observed. These results led to the conclusion that there is 
a specific protein-protein recognition between the 
A domain and its cognate PCP [19]. Such domain-specific 
aminoacylation, in fact, should be beneficial in maintain- 
ing the fidelity of a type I NRPS by providing additional 
‘gating’ against misincorporation of nonspecifically acti- 
vated aminoacyl adenylate into the final peptide product. 
As a type II PCP such as BlmI lacks its cognate A domain, 
we asked if BlmI could be aminoacylated by an unrelated 
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Figure 8 
Enzyme architecture of (a,b) type I PKS and 
NRPS and k,d) type II PKS and NRPS. A, 
adenylation domain; ACP, acyl carrier protein 
or ACP domain; AT, acyl transferase; C, 
condensation protein or C domain; K&X, 
j3-ketoacyl synthase CL subunit; KSP, 
P-ketoacyl synthase p subunit; PCP, peptidyl 
carrier protein or PCP domain. 
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A domain of a type I NRPS. Although we have yet to 
determine the biochemical role of BlmI in vivo, the fact 
that the blml gene is located in the middle of the &&n gene 
cluster suggests that it may be involved in BLM biosyn- 
thesis. To avoid the ambiguity of selecting an A domain 
that may potentially interact with BlmI in Go, we pre- 
ferred not to choose any A domain from the blm gene 
cluster to test if it could aminoacylate BlmI in trans. We 
reasoned that an A domain that is unrelated to BlmI 
should come from a gene cluster independent from BLM 
biosynthesis and should activate an amino acid not 
required by BLM. We chose Val-A because it satisfied 
both requirements. Val-A is an A domain of a type I 
NRPS from a gene cluster we have cloned previously 
from Sv ATCC15003 that has proven to be unrelated to 
BLM biosynthesis, and it specifically activates valine 
among the 23 amino acids tested (Figure 6b). Remark- 
ably, BlmI was efficiently aminoacylated by Val-A. The 
valine residue is specifically attached in a thioester 
linkage to the terminal -SH of the 4’-phosphopantetheine 
moiety of the holo-BlmI protein, as evidenced by the 
finding that the apo-BlmI was inactive under the identical 
conditions (Figure 7). 
Aminoacylation of holo-BlmI by Val-A represents the first 
example in which an A domain aminoacylates a protein 
other than its cognate PCP domain. As it has been sug- 
gested that an A domain of a type I NRPS can transfer the 
activated aminoacyl adenylate only to its cognate PCP 
domain because of the specific protein-protein recognition 
between the two domains [19], the finding that BlmI is 
aminoacylated by Val-A revealed a distinct feature of a 
type II PCP. It is very tempting to speculate that type II 
PCPs such as BlmI may have broad intrinsic substrate 
specificity towards the aminoacyl adenylate, the A domain 
or both. In fact, the latter feature is reminiscent of the type 
II PKS ACPs, which have been shown to be interchange- 
able among different PKS complexes [39-41]. The biosyn- 
thesis of D-alanyl-lipoteichoic acid in Bacih subtilis [42] 
and Lactobacihs casei [43] also involves a discrete ACP-like 
protein - the D-alanyl carrier protein - although it is 
clearly structurally and functionally different from PCPs. 
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We want to emphasize that the results we present here 
fall far short of formulating a model for a type II NRPS 
and that what we show in Figure 8d is, instead, a hypothe- 
sis modeled mainly on type II PKSs [39-41]. Neverthe- 
less, our results strongly suggest the existence of a type II 
NRPS. In fact, we have already identified two additional 
genes within the Hm gene cluster, Urn/I and HmxI 
(Figure lb), that encode type II C proteins based on 
sequence analysis (L.D., C. Sanchez, M. Chen, 
DJ. Edwards, B.S., unpublished observations). We are 
currently investigating the interactions between these 
type II C enzymes and the BlmI type II PCP in an 
attempt to constitute a functional type II NRPS for 
peptide biosynthesis. These type II NRPS proteins and 
their distinct biochemical features should now be taken 
into consideration when combinatorial biosynthesis is 
used to make novel peptides. 
Significance 
Nonribosomal peptides are synthesized by nonribosomal 
peptide synthetases (NRPSs) from a large group of pre- 
cursors to yield peptides of great structural and functional 
diversity. Many nonribosomal peptides have clinical 
applications as, for example, antibacterial, antitumor and 
immunosuppressive drugs. A greater understanding of 
peptide synthesis could lead to the manipulation of the 
process to create novel peptides. All NRPSs known to 
date are exclusively type I modular enzymes that are 
multifunctional proteins consisting of domains, such as 
adenylation (A) [91, peptidyl carrier protein (PCP) [7] 
and condensation (C) [lo] domains, for individual 
enzyme activities [2-41. These enzymes control the struc- 
tural variations of the resulting peptide products by the 
multiple-carrier thiotemplate mechanism [ 1 ,&I. Although 
individual domains of type I NRPSs can function inde- 
pendently, aminoacylation in trans ‘has been successful 
only between PCPs and their cognate A domains 17,191. 
We have cloned and sequenced the bhnl gene, overpro- 
duced and characterized the BlmI protein as a bona fide 
type II PCP, and demonstrated that the holo-BlmI can be 
aminoacylated by a completely unrelated A domain. Our 
results provide for the first time genetic and biochemical 
evidence to support the existence of a type II NRPS, 
setting the stage for formulating new research concepts to 
study peptide biosynthesis. Genetic manipulation of type I 
NRPS has already been successful in generating novel 
peptides [441. An unprecedented type II NRPS should 
shed new light on engineering NRPS proteins, signifi- 
cantly increasing our ability to produce peptides with 
even greater structural diversities. 
Materials and methods 
General DNA manipulations 
Plasmids preparation and DNA extraction were carried out using com- 
mercial kits (CIiagen, Santa Clarita, CA), and all other manipulations 
were carried out according to standard methods [45]. E. co/i strain 
DH5a was used as the host for general DNA propagations. 
Overexpression of blml in E. coli and purification of the Blml 
protein 
The b/ml gene was amplified from Sv ATCCl5003 by PCR using a 
forward primer of 5’-CCGCCCATGGGTGCTCCGCGTGGCGAGC- 
GGACCCGGCGC-3’ (the Ncol site is in italics) and a reverse primer 
of 3’-CCTAGATCTCCGGTCCCGCTCCCCCGT-5’(the Bg/ll site is in 
italics). In order to create the Ncol site, the original starting sequence 
of ‘ATG AGC’ has been changed to ‘ATG GGT’, which resulted in the 
change of the second amino acid from serine to glycine. The first five 
codons of b/ml were also optimized for overexpression in E. co/i. The 
PCR-amplified 0.3 kb Ncol-Bglll fragment was cloned into the similar 
sites of pQE-60 (Qiagen) to form pBS1. Digestion of pBS1 with Ncol 
and Hindlll and cloning the resulting 0.3 kb Ncol-Hindlll fragment into 
the same sites of PET-29a (Novagen, Madison, WI) yielded pBS2. 
Expressions of b/m/ in E. co/i Ml5 (pREP4)(pBSl) and in E. co/i 
BL-21 (DE-3)(pBSP) and purification of the resulting Blml protein by 
affinity chromatography on Ni-NTA resin were carried out under the 
standard conditions recommended by aiagen and Novagen, respec- 
tively. The incubation temperature was lowered to 30°C to improve the 
solubility. The purification of Blml was monitored by SDS-PAGE on 
15% gel. The final pure Blml protein was desalted on PD-10 column 
(Sephadex G-25, Pharmacia Biotech, Piscataway, NJ) into 50 mM 
sodium phosphate buffer, pH 7.8, containing 200 mM NaCI, 10 mM 
MgCI,, 2 mM dithiothreitol (DTT), 1 mM EDTA, 1 Oo/, glycerol, and 
stored at -80 “C for in vitro assays. 
HPLC analysis and MALDI-TOF mass spectral determination 
Samples of Blml (30-70 pg) purified from E. co/i OG7001 (pBS2) or 
f. co/i OG7001 (pBS2/pDPT-Gsp) were analyzed on a Nova-Pak Cl 8 
column (5 mm x 10, Waters, Milford, MA) using a Rainin DMAX HPLC 
unit. The column was developed by a linear gradient of O-50% aceto- 
nitrile in 0.1% trifluoroacetic acid in 25 min, followed by additional 
5 min at 50% acetonitrile, with a flow rate of 0.6 ml/min and detection 
at 280 nm. MALDI-TOF mass spectral determination was performed on 
a Bruker Biflex Ill1 spectrometer at the Facility for Advanced Instrumen- 
tation of University of California, Davis. 
In vivo labeling of Blml with [3-3H]-p-alanine 
The p-alanine auxotroph E. co/i strain OG7001 [35] was transformed 
with pBS2 and cultured under the same conditions as for f. co/i 
BL21 (DE3) (Novagen). For co-expression of b/ml with gsp, pDPT-Gsp 
[26] was similarly transformed into E. co/i OG7001 (pBS2) and the 
transformants were cultured in PxYT 1431 in the presence of kanamycin 
(25 pg/ml) and chloramphenicol (50 pg/ml). For in t&o labeling experi- 
ment, cells from 2 ml overnight culture of either E. co/i OG7001 (pBS2) 
or E. co/i OG7001(pBSP/pDPT-Gsp) were harvested, washed with 
M9 minimal medium [43], and re-suspended in 2 ml of MS minimal 
medium. The latter were used as seed cultures (20 ~1) to inoculate 1 ml 
M9 medium with kanamycin (25kg/ml) or kanamycin (25pglml) and 
chloramphenicol (50 pg/ml) for E. co/i OG7001 (pBS2) or E. co/i 
OG7001 (pBSP/pDPT-Gsp), respectively. The resulting culture was 
incubated at 30°C 250 rpm to ODsoonm 0.6 and to this was added 
10 pCi of [3-3H]-P-alanine (50 Ci/mmol, American Radiolabeled Chem- 
icals Inc., St. Louis, MO) with or without IPTG (1 mM). Total proteins 
were resolved by SDS-PAGE on 15% gels that were Coomassie blue- 
stained. To determine sH-labeling of the overproduced holo-Blml 
protein, gels were soaked in Amplifier (Amersham, Arlington Heights, II) 
for 20 min, dried between two sheets of cellulose membrane (KOH 
Development Inc., Ann Arbor, MI), and visualized by autoradiography on 
X-ray films (Fuji Medical Systems, Stamford, CT). 
In vitro labeling of Blml with [3H-pantetheinel-CoA 
Expression of sfp in E. co/i MVl 1 SO(pUCB-Sfp), purification of the Sfp 
PPTase to homogeneity, and 4’-phosphopantetheinylation of apo-Blml 
by Sfp in vitro were carried out essentially according to literature pro- 
cedures [24,37]. A typical 100 pl assay solution contained 26 pM apo- 
Blml, 2.9 PM Sfp, 25 FM [3H-pantetheine]-CoA (0.9 pCi, 40 Ci/mM), 
10 mM MgCI,, and 5 mM DTT, in 75 mM MESlNaOAc buffer, pH 6.0. 
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After 30 min incubation at 37’C, the assays were stopped by addition 
of 5 ul of bovine serum albumin (0.2 mglml) and 0.9 ml of cold 10% 
(v/v) trichloroacetic acid (TCA). The precipitated proteins were col- 
lected by centrifugation at 14,000 rpm, 20 min, 4°C (Eppendorf 
5415C centrifuge), washed with 10% TCA three times, and resolved 
using SDS-PAGE on 15% gel. The 3H-activity incorporated into holo- 
Blml was similarly determined by autoradiography as described for in 
viva labeling of holo-Blm with [3-3Hl-8-alanine. 
Overexpression of val-A in E. coli and purification and assay of 
the Val-A protein 
The v&A fragment was amplified from Sv ATCCl5003 by PCR using 
a forward primer of B’-GGAATTCCATATGGGCACCACCGTCGC- 
CGCG-3’ (the Ndel site is in italics), and a reverse primer of 3’-GGCA- 
AGCTTGGGACCGGGCGTGGAGCGC (the /-/indIll site is in italics). 
The PCR-amplified 1.6 kb Ndel-HindIll fragment was cloned in the 
similar sites of PET-28a (Qiagen) to yield pBS3. Expression of val-A in 
E. co/i BL-21(DE-3)(pBS3) and purification of the resulting Val-A 
protein using affinity chromatography on Ni-NTA resin were carried out 
under the standard conditions recommended by Novagen. 
Amino acid-dependent ATP-PPi assays were performed essentially 
according to the literature procedures 126,381. A typical 100 f.~l assay 
solution contained 180 nM Val-A, 1 mM ATP, 0.1 mM PPi with 0.2 J.&i 
of 32P-PPi (11.75 Cilmmol, NEN Life Science Products, Inc., Boston, 
MA), 1 mM MgCI,, 0.1 mM EDTA, and 1 mM L-amino acid in 50 mM 
sodium phosphate buffer, pH 7.8. After 30 min incubation at 30 ‘C, the 
assays were stopped by addition of 0.9 ml of cold 1% (w/v) activated 
charcoal in 30/, (v/v) perchloric acid. The precipitates were collected on 
glass fiber filters (2.4 cm, G-4, Fisher, Pittsburgh, PA), washed succes- 
sively with 10 ml of 0.2 M sodium phosphate buffer, pH 8.0, 4 ml water, 
and 1 ml of ethanol, and dried in air. The filters were mixed with 7 ml of 
scintillation fluid (ScintiSafe Gel, Fisher) and counted on a Beckman 
LS-6800 scintillation counter to determine the radioactivity. 
In vitro aminoacylation of holo-Blml by Val-A 
The aminoacylation of holo-Blml was carried out essentially according to 
literature methods [7,191. A typical 100 pl assay solution contained 
180 nM Val-A, 1.5-2.8uM apo- or holo-Blml, 35 pM L-[14C(U)]-valine 
(283 mCi/mmol, NEN Life Science Products, Inc., Boston, MA), 5 mM 
ATP, 10 mM MgCI,, and 5 mM DTT in 75 mM Tris-HCI buffer, pH 8.0. 
The reactions were started by the addition of ATP and, after incubation 
at 37°C for 30 min, were stopped by addition of 0.9 ml of cold 70/, (v/v) 
TCA. The precipitated proteins were collected by centrifugation at 
14,000 rpm, 20 min, 4% (Eppendorf 5415C centrifuge) and resolved by 
SDS-PAGE on a 15% gel. The radioactivity incorporated into the holo- 
Blml-L-[14C(U)]valine species was similarly determined using autoradiog- 
raphy as described for in viva labeling of holo-Blml with [3-3H]-5-alanine. 
Accession numbers 
The b/m/ gene sequence has been deposited in GenBank under the 
accession number AFl49091. 
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